Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway

Earnings Call Insights: Humacyte, Inc. (HUMA) Q2 2025

MANAGEMENT VIEW

* CEO Laura E. Niklason reported significant expansion in commercial access for Symvess, following its FDA approval for extremity vascular trauma, stating, "a total of 13 organizations have completed the VAC process and have approved the purchase of Symvess... a total of 82 civilian hospitals are now eligible to purchase Symvess. This is an enormous increase from the 5 civilian hospitals that were eligible to purchase Symvess at our last quarterly earnings call." Niklason highlighted the first sale to a U.S. military facility and the product's ECAT listing, making Symvess available to 35 military treatment facilities and 160 VA hospitals. She noted, "July product sales of approximately $0.3 million exceeded the total sales that we recorded for the first half of the year."
* Niklason addressed CMS's denial of the new technology add-on payment (NTAP) for Symvess, but downplayed its impact, explaining, "only about 4.3% of vascular trauma patients... are covered under Medicare reimbursement," and emphasized ongoing discussions with private payers for supplemental reimbursement.
* Niklason detailed progress in the ATEV pipeline for dialysis access, referencing recent V007 Phase III trial results: "Among this high-risk cohort functional patency at 6 months and secondary patency at 12 months were significantly higher in ATEV recipients as compared with fistula. Duration of access usability over the first year was also significantly higher in the ATEV group at 8 months versus only 4.5 months for arteriovenous fistula with a p-value of 0.0002."
* CFO Dale A. Sander stated, "We reported $0.3 million in revenue for the second quarter of 2025... The remaining $0.2 million resulted from a research collaboration with a large medical technology company." Sander also highlighted cost reductions: "we implemented a plan to reduce our workforce by 30 employees, defer additional planned new hires and reduce other operating expenses... Net savings are estimated to be up to approximately $38 million in 2026 for a total estimated savings of over $50 million in 2025 and 2026 relative to the original budget forecast."

OUTLOOK

* Niklason announced a new Symvess price point of $24,250 effective July 1, stating, "by coming in below $25,000, this has increased the ease with which VAC committees can review our product and agree to bring it on to the shelf."
* The company aims to complete enrollment of 150 patients in the V012 Phase III trial for dialysis access by year-end 2025, with interim analysis planned for April 2026. Niklason said, "Subject to these interim results, Humacyte's plan is to submit a supplemental BLA in the second half of 2026, including data from V012 and the V007 Phase III pivotal studies to expand the Symvess label and add AV access for hemodialysis as an indication."

FINANCIAL RESULTS

* Sander reported $0.3 million in Q2 revenue, of which $0.1 million related to U.S. Symvess sales and $0.2 million from a research collaboration. Cost of goods sold was $0.2 million.
* R&D expenses were $22.0 million for Q2, down from $23.8 million year-over-year, with the decrease attributed to capitalization of overhead costs post-commercial launch.
* Selling, general and administrative expenses rose to $7.8 million from $5.7 million, reflecting commercial launch activities.
* Net loss for Q2 was $37.7 million, compared to $56.7 million a year ago. Cash, cash equivalents, and restricted cash stood at $88.4 million as of June 30, 2025.

Q&A

* Ryan Benjamin Zimmerman, BTIG: Asked about the July sales uptick and pricing strategy. Niklason attributed growth to time and VAC approvals, and confirmed the price decrease to $24,250 as the new standard for the next year.
* Joshua Thomas Jennings, TD Cowen: Inquired about real-world evidence to counter detractors. Niklason said a post-approval trauma registry is planned and that accumulating real-world evidence and publications will support commercial efforts. Scheessele added that public attacks mainly slowed the VAC approval process.
* Jennings also asked about VA/military channel traction. Scheessele explained parallel efforts targeting individual facilities and potential bulk purchases, expecting deeper penetration through year-end and into 2026.
* Jennings questioned V012 trial enrollment timelines. Niklason aimed to complete 150 patients by year-end 2025, with interim analysis in April 2026 and top-line results expected by May or June.
* Swayampakula Ramakanth, H.C. Wainwright: Asked about VAC conversion rates and CMS denial impact. Scheessele said 12 hospitals ordered Symvess, with reorders noted. Niklason and Scheessele stressed that private payers are more significant than Medicare for reimbursement.
* Bruce David Jackson, Benchmark: Sought an update on the coronary artery bypass graft program. Niklason noted a primate study publication is forthcoming and IND filing expected later in 2025, aiming for a 2026 clinical trial.

SENTIMENT ANALYSIS

* Analysts focused on commercial traction, pricing, and payer dynamics, showing neutral to slightly positive sentiment. Their tone indicated cautious optimism and a desire for clarity on sales momentum and clinical progress.
* Management remained confident, referencing "traction" and "progress" repeatedly, and responded to challenges by emphasizing pipeline advances and cost-saving actions. Prepared remarks were upbeat, while Q&A responses were measured and pragmatic.
* Compared to the previous quarter, both analysts and management appeared more optimistic, supported by a larger base of eligible hospitals and tangible increases in commercial activity. Management’s tone was less defensive and more focused on execution.

QUARTER-OVER-QUARTER COMPARISON

* The number of VAC-approved hospitals eligible to purchase Symvess increased from 5 to 82, with total eligible facilities now exceeding 200, including military and VA centers. The previous quarter had 45 VAC processes initiated.
* Commercial sales activity accelerated, with July sales surpassing sales for the entire first half of the year.
* New pricing was introduced, and cost-saving initiatives intensified with $38 million in anticipated 2026 savings, up from the prior estimate of $13.8 million for 2025.
* Analyst questions shifted from uncertainty about initial uptake to deeper inquiries on scaling sales, price strategy, and pipeline milestones.
* Management’s confidence in both pipeline progress and commercial execution increased, with a stronger emphasis on payer engagement and supplemental reimbursement.

RISKS AND CONCERNS

* Niklason acknowledged headwinds from public attacks that slowed VAC approvals, but indicated acceleration had resumed. She also flagged the CMS NTAP denial, though described the commercial impact as limited due to payer mix.
* Scheessele cited economic conditions and public attacks as factors slowing hospital adoption but stated that a robust sales funnel should help mitigate delays.
* Both management and analysts recognized the importance of private payer negotiations and continued real-world evidence to support adoption and reimbursement.

FINAL TAKEAWAY

Humacyte emphasized its significant expansion in commercial access for Symvess, now available to over 200 hospitals, and its strategic pricing shift to foster further VAC approvals. The company highlighted continued progress in its dialysis access pipeline and reaffirmed confidence in its ability to drive value through disciplined cost controls, expanding hospital reach, and clinical pipeline momentum. Management remains focused on executing commercial contracts, advancing clinical trials, and securing broader reimbursement as primary levers for growth through the remainder of 2025 and beyond.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/huma/earnings/transcripts]

MORE ON HUMACYTE

* Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4812165-humacyte-inc-huma-q2-2025-earnings-call-transcript]
* Humacyte: Revenue Ramp From Symvess Incoming [https://seekingalpha.com/article/4794043-humacyte-revenue-ramp-from-symvess-incoming]
* Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey [https://seekingalpha.com/article/4793333-humacyte-stock-paradoxically-scales-back-symvess-begins-its-long-journey]
* Humacyte GAAP EPS of -$0.24 misses by $0.08, revenue of $0.3M misses by $0.7M [https://seekingalpha.com/news/4483120-humacyte-gaap-eps-of--024-misses-by-008-revenue-of-03m-misses-by-07m]
* Humacyte rises on Symvess sale to military treatment facility [https://seekingalpha.com/news/4470877-humacyte-rises-on-symvess-sale-to-military-treatment-facility]